يعرض 1 - 20 نتائج من 139 نتيجة بحث عن '"Gomez-Roca, C."', وقت الاستعلام: 0.62s تنقيح النتائج
  1. 1
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
  5. 5
    Academic Journal

    المساهمون: Université de Lille, CHU Lille, Centre Léon Bérard Lyon, Département d’Innovation Thérapeutique et essais précoces Gustave Roussy DITEP, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD, Centre Hospitalier Universitaire CHU Grenoble CHUGA, Institut Bergonié Bordeaux, Institut de Cancérologie de l'Ouest Angers/Nantes UNICANCER/ICO, Centre Régional de Lutte contre le Cancer François Baclesse Caen UNICANCER/CRLC, Centre Régional de Lutte contre le cancer Georges-François Leclerc Dijon UNICANCER/CRLCC-CGFL, Centre Hospitalier Universitaire de Nantes CHU Nantes, Institut Curie Paris, Hopital Saint-Louis AP-HP AP-HP, Institut Claudius Regaud, Institut Paoli-Calmettes IPC, Aix Marseille Université AMU, CRLCC Eugène Marquis CRLCC, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

    مصطلحات موضوعية: early-phase clinical trial, cancer, social inequalities, access

    Relation: European Society for Medical Oncology; ESMO Open; http://hdl.handle.net/20.500.12210/103720

  6. 6
    Academic Journal

    المساهمون: Université de Lille, CHU Lille, Centre Léon Bérard Lyon, CHU Clermont-Ferrand, Institut Gustave Roussy IGR, CHU Pitié-Salpêtrière AP-HP, Centre Hospitalier Régional Universitaire Montpellier CHRU Montpellier, Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU de Poitiers, Hospices Civils de Lyon HCL, Institut Bergonié Bordeaux, Hôpital Dupuytren CHU Limoges, Pôle de Chirurgie Oncologique générale, Gynécologique et Mammaire Centre Antoine-Lacassagne, Centre Hospitalier Régional Universitaire CHU Lille CHRU Lille, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle ICM, CHU Caen, Institut Mutualiste de Montsouris IMM, Service de dermatologie Avicenne, Centre Hospitalier Universitaire CHU Grenoble CHUGA, Centre Régional de Lutte contre le Cancer Oscar Lambret Lille UNICANCER/Lille, CHU Saint-Antoine AP-HP, UNICANCER

  7. 7
    Academic Journal

    المساهمون: B. Gyawali, E.G.E. de Vrie, U. Dafni, T. Amaral, J. Barriuso, J. Bogaert, A. Calle, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudaki, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G. Zarkaveli, C. Zielinski, P. Zygoura, N.I. Cherny

    Relation: info:eu-repo/semantics/altIdentifier/pmid/33887690; info:eu-repo/semantics/altIdentifier/wos/WOS:000663044500017; volume:6; issue:3; numberofpages:11; journal:ESMO OPEN; http://hdl.handle.net/2434/839591; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85108742259

  8. 8
  9. 9
    Academic Journal
  10. 10
  11. 11
  12. 12
    Academic Journal
  13. 13
    Conference

    المساهمون: Institut Curie, Paris, France

    Relation: https://dx.doi.org/10.1136/jitc-2022-SITC2022.0774; Le Tourneau C, Piha-Paul S, Prenen H, Delafontaine B, Pinato D, Santoro A, et al. A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule Pd-L1 Inhibitor, Incb086550, in Patients with Select Advanced Tumors. Journal for immunotherapy of cancer. 2022 Nov;10:A805-A. PubMed PMID: WOS:000919423400730.; http://hdl.handle.net/10541/626278; Journal for Immunotherapy of Cancer

  14. 14
    Conference

    المساهمون: Fundación Arturo López Pérez, Providencia, Santiago, Chile

    Relation: https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4080; Villanueva L, Lwin Z, Chung HCC, Gomez-Roca CA, Longo F, Yanez E, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. Vol. 39, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021. p. 4080–4080.; http://hdl.handle.net/10541/624881; Journal of Clinical Oncology

  15. 15
    Conference

    المساهمون: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center,Yonsei University College of Medicine, Seoul, South Korea

    Relation: https://dx.doi.org/10.1016/j.annonc.2021.05.194; Chung H, Villanueva L, Graham D, Saada-Bouzid E, Ghori R, Kubiak P, et al. P-139 A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort. Annals of Oncology. 2021 Jul;32:S146.; http://hdl.handle.net/10541/624429; Annals of Oncology

  16. 16
    Conference

    المساهمون: Fundación Arturo López Pérez, Providencia, Santiago, Chile

    Relation: https://dx.doi.org/10.1200/JCO.2021.39.3_suppl.321; Villanueva L, Lwin Z, Chung HC, Gomez-Roca C, Longo F, Yanez E, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. JCO. 2021 Jan 20;39(3_suppl):321–321.; http://hdl.handle.net/10541/623999; Journal of Clinical Oncology

  17. 17
    Conference

    المساهمون: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

    Relation: https://dx.doi.org/10.1200/JCO.2021.39.3_suppl.230; Chung HC, Lwin Z, Gomez-Roca C, Longo F, Yanez E, Castanon Alvarez E, et al. LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort. JCO. 2021 Jan 20;39(3_suppl):230–230.; http://hdl.handle.net/10541/623995; Journal of Clinical Oncology

  18. 18
    Conference

    المساهمون: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

    Relation: https://dx.doi.org/10.1158/1538-7445.SABCS20-PS12-07; Chung HC, Saada-Bouzid E, Munoz FL, Yanez E, Im SA, Castanon E, et al. Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study Cancer Research. 2021;81(4).; http://hdl.handle.net/10541/623913; Cancer Research

  19. 19
  20. 20